All In Biotech

Drug Trial Radar · NCT05489276

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Phase I Clinical Trial of TQB2825 Injection in Subjects With CD20 Positive Hematological Tumors

Last checked: Nov 19, 2026Latest source record: Aug 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 22, 2022

Primary completion

Oct 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-group, open, dose escalation and expansion Phase I clinical study, with phase I being a dose escalation study and Phase II being a dose expansion study. The purpose of this study was to evaluate the safety and tolerability of TQB2825 injection in CD20-positive hematological tumor subjects, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) (if any), or optimal biological dose (OBD), and recommended phase II dose (RP2D).

Conditions

  • Hematological Tumors

Interventions

  • TQB2825 injectionDrug

    TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity(DLT)Time frame: 104 weeks
  2. the maximum tolerated dose (MTD)Time frame: 104 weeks
  3. Recommended Phase II Dose(RP2D)Time frame: 104 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.